Oxford Nanopore Technologies PLC (4R0) AI Stock Analysis
Oxford Nanopore Technologies PLC
(XETRA:4R0)
No summary available
Oxford Nanopore Technologies PLC (4R0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 2.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 3,452
- Price to Earnings (P/E)
- -16.8
- Beta (1Y)
- 0.62
- Revenue Growth
- 11.03%
- EPS Growth
- 19.63%
- Country
- Germany
- Employees
- 1,314
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oxford Nanopore Technologies PLC Business Overview & Revenue Model
Company Description
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for ana...
Oxford Nanopore Technologies PLC Earnings Call Summary
The call presents a constructive operational and financial progression: strong top‑line growth (+24.2% constant currency), marked shift toward higher‑value applied markets (clinical +59%), meaningful margin improvements and a stronger cash position (GBP 302.8m). Management has executed strategic reprioritization and cost discipline, delivering a 26% improvement in adjusted EBITDA and guiding to FY26 growth (21–25% ccy) and FY26 gross margin expansion (62%). Key negatives are ongoing adjusted EBITDA and cash losses (with breakeven targeted in 2027/2028), one‑off margin hits (obsolete inventory and FX), restructuring costs, product discontinuations/pauses (P2 Solo, ElysION), delays to some product launches (PromethION timing) and market‑specific headwinds (China/APAC export controls). Overall, positives—broad growth, margin momentum, cash runway, and clearer strategic focus—outweigh the remaining execution and market risks, with management articulating a credible path to profitability.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided FY26 revenue growth of 21–25% at constant currency, a 62% gross‑margin target and 0–5% adjusted OpEx growth, while reiterating medium‑term targets of adjusted‑EBITDA breakeven in 2027 and cash‑flow breakeven in 2028 with minimum cash of >£100m. They pointed to FY25 results that support this outlook: 24.2% constant‑currency revenue growth (above prior 20–23% guide), 26% improvement in adjusted EBITDA (GBP 31.2m), adjusted OpEx growth of just 1%, reported gross margin of 58.6% (see‑through nearer 61%), cash of £302.8m, net cash outflow of £101m, inventory down £18m, CapEx and capitalized development of £45.5m, and working‑capital inflow of £13.4m. Management expects continued above‑market, broad‑based growth (clinical +59%, biopharma +30%, applied industrial +27%, research +15%), stronger growth in the Americas, further margin upside from PromethION recycling and the CapEx‑first pricing model, but flags near‑term regional headwinds (EMEA contract timing and APAC/China/PRECISE II) that underpin the guidance range.
Oxford Nanopore Technologies PLC Peers Comparison
Overall Rating
GB:BVXP89Outperform
GB:4BB52Neutral
GB:AVCT43Neutral
GB:OBD40Underperform
GB:APTA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:BVXP | 89Outperform | GBP 107.11M | 13.96 | 67.81% | 7.41% | -1.10% | 0.32% |
| GB:4BB | 52Neutral | GBP 82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:AVCT | 43Neutral | GBP 279.90M | -6.30 | -1293.07% | ― | ― | ― |
| GB:OBD | 40Underperform | GBP 13.78M | -0.26 | -451.74% | ― | 33.37% | 86.41% |
| GB:APTA | 37Underperform | GBP 9.88M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:4R0 | Oxford Nanopore Technologies PLC | 2.55 | 1.04 | 69.14% | |
| GB:AVCT | Avacta Group plc | 57.50 | -15.50 | -21.23% | |
| GB:BVXP | Bioventix plc | 2025.00 | -20.67 | -1.01% | |
| GB:OBD | Oxford BioDynamics | 0.10 | -0.20 | -66.00% | |
| GB:4BB | 4basebio UK Societas | 530.00 | -255.00 | -32.48% | |
| GB:APTA | Aptamer Group Plc | 0.28 | -0.52 | -64.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.